Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787061 | 0.84 | CES2 (0.47) | CES2CES1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL14605537 | 0.82 | CES2 (0.57) | CES2CES1NLRP3CA12CA1 | |
| SCHEMBL884596 | 0.82 | CES2 (0.50) | CES2CES1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9451631 | 0.77 | CES2 (0.49) | CES2CES1CA12CA1CA2 | |
| SCHEMBL884443 | 0.77 | ALDH1A1 (0.59) | CES2CES1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3709449 | 0.77 | CYP11B1 (0.43) | NLRP3SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL3711139 | 0.76 | CES2 (0.57) | CES2CES1RAB9AKMT2AMEN1 | |
| SCHEMBL2070179 | 0.74 | L3MBTL1 (0.45) | CES2CES1ALDH1A1MAPTRAB9A | |
| SCHEMBL19398550 | 0.74 | LMNA (0.42) | CES2CES1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL615787 | 0.74 | NAPRT (0.44) | ALDH1A1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398324-B1 | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8653079-B2 | Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8486946-B2 | Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130102599-A1 | PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
| US-20110301167-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301167-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, MTNR1A | CES2 1596/4885CES1 1575/4885NLRP3 1582/4885 |
| US-20130102599-A1 | PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, MTNR1A | CES2 1596/4885CES1 1575/4885NLRP3 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.